Company
Takeda
Takeda has 48 drugs tracked on RxWires: 7 post-market, 1 approved, 20 in Phase 3, 3 in Phase 2/3, 7 in Phase 2, 2 in Phase 1/2, 8 in Phase 1.
- Ticker
- TAK
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Vonoprazan | Post-Market | Erosive Esophagitis |
| Lisdexamfetamine dimesylate | Post-Market | Attention-deficit/Hyperactivity Disorder |
| Ramelteon | Post-Market | ADHD With Sleep Onset Insomnia |
| ARALAST Alpha1-Proteinase Inhibitor | Post-Market | Alpha1-antitrypsin Deficiency |
| Alpha1-proteinase inhibitor | Post-Market | Alpha1-antitrypsin Deficiency |
| Octocog alfa (recombinant human coagulation factor VIII) | Post-Market | Hemophilia A |
| Pioglitazone | Post-Market | Diabetes Mellitus, Type 2 |
| LIALDA | Approved | |
| IGSC 20% infusion | Phase 3 | Primary Immunodeficiency Disease |
| SPD489 | Phase 3 | ADHD |
| Alogliptin | Phase 3 | Diabetes Mellitus |
| Vortioxetine | Phase 3 | Generalized Anxiety Disorder |
| Elritercept | Phase 3 | Myelodysplastic Syndromes |
| TAK-279 | Phase 3 | Generalized Pustular Psoriasis |
| Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) |
| TAK-861 | Phase 3 | Narcolepsy Type 1 (NT1) |
| Vedolizumab IV | Phase 3 | Crohn's Disease |
| Zasocitinib | Phase 3 | Palmoplantar Psoriasis |
| Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) | Phase 3 | Major Depressive Disorder |
| TAK-003 | Phase 3 | Dengue Fever |
| Cyproterone acetate | Phase 3 | Adenocarcinoma, Prostate |
| TAK-928 | Phase 3 | IO Resistant Squamous and Nonsquamous NSCLC |
| PEGylated Recombinant Factor VIII | Phase 3 | Hemophilia A |
| TAK-667 | Phase 3 | Hereditary Angioedema |
| Tacrolimus | Phase 3 | Ulcerative Colitis |
| TAK-881 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) |
| TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) |
| Fosrenol (Lanthanum Carbonate) | Phase 3 | Chronic Kidney Disease, Stage 5 |
| TAK-360 | Phase 2/3 | Idiopathic Hypersomnia |
| GLASSIA | Phase 2/3 | Graft Versus Host Disease |
| Antihemophilic factor, recombinant, manufactured protein-free | Phase 2/3 | Hemophilia A |
| Dexlansoprazole | Phase 2 | Barrett's Esophagus |
| TAK-411 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) |
| TAK-063 20 mg | Phase 2 | Schizophrenia |
| NDI-034858 study drug | Phase 2 | Moderate to Severe Plaque Psoriasis |
| Rusfertide | Phase 2 | Polycythemia Vera |
| Lapaquistat acetate and fenofibrate | Phase 2 | Hyperlipidemias |
| TAK-101 | Phase 2 | Celiac Disease |
| B-MAD chemotherapy | Phase 1/2 | Extranodal NK/T-cell Lymphoma |
| Brentuximab vedotin | Phase 1/2 | Hodgkin Disease |
| Mobocertinib | Phase 1 | Non-Small Cell Lung Cancer |
| TAK-438 | Phase 1 | Ascending Single Dose Study |
| TAK-058 | Phase 1 | Healthy Volunteers |
| TAK-648 | Phase 1 | Healthy Volunteers |
| teduglutide | Phase 1 | Healthy Volunteers |
| Lubiprostone | Phase 1 | Other Constipation |
| Ixazomib | Phase 1 | Glioblastoma |
| Soticlestat | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Takeda on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.